<DOC>
	<DOCNO>NCT00990990</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics multiple dos PNU-100480 give 14 28 day . Killing activity bacterium cause tuberculosis ( TB ) also measure . The effect add additional tuberculosis ( TB ) agent ( give 2 day ) addition PNU-100480 evaluate . Linezolid open label determine activity whole blood assay ( WBA ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics And Measurement Of Whole Blood Activity ( WBA ) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers</brief_title>
	<detailed_description>Evaluate safety , tolerability , pharmacokinetics whole blood activity ( WBA ) PNU-100480 give 14 28 day ; evaluate WBA PNU pyrazinamide ; evaluate WBA linezolid</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Healthy adult volunteer willing able confine Clinical Research Unit comply study schedule . Women nonchildbearing potential . History hypersensitivity , intolerance , linezolid . Antibiotic treatment within 14 day prior dose , previous antibiotic use discretion investigator . Previous history irritable bowel syndrome ( IBS ) inflammatory bowel disease ( IBD ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Safety tolerability pharmacokinetics ( PK ) pharmacodynamics whole blood activity ( WBA ) PNU-100480 linezolid pyrazinamide multiple dose</keyword>
</DOC>